Oryzon Genomics (BME: ORY)

Last close As at 22/02/2024

EUR1.87

−0.01 (−0.43%)

Market capitalisation

EUR116m

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset Vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder, and is in a Phase IIb trial for schizophrenia.

Oryzon is among the leading clinical-stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and a potentially favourable safety/efficacy profile compared with the first-generation HDAC inhibitors.

Latest Insights

View More

Healthcare | Update

Oryzon Genomics — PORTICO update with planned FDA EoP2

Healthcare | edison tv

Executive interview with Carlos Buesa, CEO of Oryzon Genomics

Healthcare | Flash note

Oryzon Genomics — Grant to bolster ALS pipeline, add funding

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Carlos Buesa

    CEO

Balance Sheet

Forecast net debt (€m)

5.2

Forecast gearing ratio (%)

8

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (2.4009) (6.9652) (23.9837)
Relative (4.045) (9.273) (31.2278)
52 week high/low €2.5/€1.9

Financials

Oryzon’s two lead drugs are vafidemstat for CNS indications and iadademstat for oncology (both are small molecule inhibitors of LSD1, an epigenetic target). In CNS, the Phase IIb PORTICO trial (borderline personality disorder, results announced in January 2024) did not meet the primary endpoint with statistical significance, but vafidemstat was favoured over placebo in all efficacy measures with statistical significance in key secondary endpoints; management plans to request an end-of-Phase II meeting with the FDA to discuss a potential registrational Phase III programme. The Phase IIb EVOLUTION trial (schizophrenia) is ongoing. Oryzon is also deploying a CNS personalised medicine approach with its Phase I/II HOPE trial (Kabuki syndrome), expected to start in 2024. In oncology, the ongoing FRIDA trial (AML) and planned STELLAR trial (SCLC) may be pivotal; the FDA has granted Orphan Drug designation for iadademstat in these indications. FRIDA represents one of Oryzon’s key strategic priorities in oncology.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 10.6 (6.9) (7.2) (8.83) N/A N/A
2022A 15.7 (5.3) (6.4) (7.26) N/A N/A
2023E 15.9 (5.2) (6.6) (7.15) N/A N/A
2024E 19.0 (9.3) (10.0) (12.83) N/A N/A

Further insights

insight

Epigenetics

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free